Reference number
1745-H

SPECIALTY QUANTITY LIMIT PROGRAM

KINERET (anakinra)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. If the member's plan allows a quantity limit exception review for the requested medication, coverage of an additional quantity may be provided up to the exception limit with prior authorization.

II. COVERED QUANTITIES

Medication	Standard Limit	Exception Limit	FDA-recommended dosing
Kineret (anakinra) injection 100 mg/0.67 mL single-use prefilled syringe	240 syringes per 30 days	360 syringes per 30 days*	• Rheumatoid arthritis: 100 mg per day • Cryopyrin-Associated Periodic Syndromes (CAPS)/Neonatal-Onset Multisystem Inflammatory Disease (NOMID): up to 8 mg/kg per day

* Coverage up to the exception limits may be provided with prior authorization via the Specialty Post Limit Quantity Exception Criteria for approval.

III. REFERENCE

1. Kineret [package insert]. Stockholm, Sweden: Swedish Orphan Biovitrum AB (publ); June 2018.